The new strategies for treatment of ovarian cancer with platinum-resistance which pay its attention to platinum concentration in cell

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462517
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: University of Fukui
• Principal Investigator: KUROKAWA Tetsuji 福井大学, 学術研究院医学系部門, 准教授 (60334835)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: Ovarian cancer / Cisplatin / hCtr-1

Outline of Final Research Achievements

[Introduction] The objective of our research is to make clear the mechanism of platinum-resistance in ovarian cancer. Many researchers have reported lots of mechanism about platinum-resistance. We focus on the pharmacological resistance. Pharmacological resistance is to inhibit that drug put into the cell and adduct the DNA. Especially, we researched the function of human Cupper transporter-1human cupper transporter-1 (hCtr-1). hCTR1 protein is the influx transporter. The function of this transporter makes platinum-drug put into the cell. [Result] There is no difference of hCTR1 expression between short PFS and long PFS. One of the resistant mechanism in mucinous adenocarcinoma or clear cell carcinoma may be low expression of hCTR1. [Conclusion] Our study suggests the possibility that expression of hCTR1 in ovarian carcinomas is clinically correlated with histological type. These results may be useful to overcome the platinum-resistance in ovarian carcinoma.

Free Research Field

婦人科腫瘍